Critical Review: Disc Medicine (NASDAQ:IRON) versus Bolt Biotherapeutics (NASDAQ:BOLT)

Bolt Biotherapeutics (NASDAQ:BOLT) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Insider and Institutional Ownership

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bolt Biotherapeutics and Disc Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Disc Medicine	N/A	-36.94%	-33.88%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bolt Biotherapeutics and Disc Medicine, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1	1	3	0	2.40
Disc Medicine	1	1	9	0	2.73

Bolt Biotherapeutics currently has a consensus target price of $34.67, suggesting a potential upside of 676.41%. Disc Medicine has a consensus target price of $104.44, suggesting a potential upside of 40.44%. Given Bolt Biotherapeutics’ higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Disc Medicine.

Volatility and Risk

Bolt Biotherapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Valuation & Earnings

This table compares Bolt Biotherapeutics and Disc Medicine”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70 million	1.11	-$33.38 million	($16.33)	-0.27
Disc Medicine	N/A	N/A	-$212.18 million	($6.62)	-11.23

Bolt Biotherapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Bolt Biotherapeutics beats Disc Medicine on 7 of the 13 factors compared between the two stocks.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

About Disc Medicine

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company’s preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.